Also known as: Synagis (brand); Anti-RSV monoclonal antibody
Palivizumab is a humanized monoclonal antibody directed against an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Manufactured by Mediocon Inc at its GMP-certified facility in Maharashtra, India, it is used for prophylaxis of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk.
| Parameter | Specification |
|---|---|
| CAS Number | 216995-50-1 |
| Molecular Formula | C6499H9917N1717O2014S46 |
| Molecular Weight | ~149,000 g/mol |
| Grade | IP / BP / USP |
| Category | Monoclonal Antibody / Antiviral Agent |
| Appearance | White to off-white lyophilized powder |
| Solubility | Freely soluble in water, slightly soluble in phosphate buffered saline |
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Batch No | PAV/24032026 |
| Mfg Date | MAR 2026 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Palivizumab — CAS 216995-50-1 (CAS 216995-50-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Palivizumab — CAS 216995-50-1 is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance